| | Characteristic | (%) or median (range) |
| | Patients | 71 | | Age, years, median (range) | 66 (37–92) | | Gender | | | Male | 59 (83.1) | | Female | 12 (16.9) | | Hemoglobin, g/dL, median (range) | 9.6 (3.80–17.10) | | Platelet count, ×109/L, median (range) | 213 (23–575) | | ALC, ×109/L, median (range) | 1.70 (0.10–12.30) | | CRP, mg/dL, median (range) | 2.44 (0.05–23.80) | | Serum 2-microglobulin, mg/L, median (range) | 4.20 (1.34–30.00) | | Serum albumin, g/dL, median (range) | 3.2 (1.50–4.60) | | LDH, IU/L, median (range) | 261.0 (74.0–968.0) | | BM lymphocyte, %, median (range) | 14 (5–100) | | Cytogenetic abnormalities, present (%) | 8 (11.3%) | | Serum monoclonal protein, mg/dL, median (range) | 3640.0 (18.30–10795.0) | | B symptom, present (%) | 8 (11.3) | | ECOG (%) ≥2 | 23 (32.4) | | Hyperviscosity, present (%) | 8 (11.3) | | Lymphadenopathy, yes (%) | 27 (38.0) | | Extranodal involvement, yes (%) | 29 (40.8) | | Splenomegaly, yes (%) | 18 (25.4) | | Hepatomegaly, yes (%) | 7 (9.9) | | ISS (%) | | | I | 13 (18.3) | | II | 26 (36.6) | | III | 26 (36.6) | | Unknown | 6 (8.5) | | Treatment regimen | | | Novel agent combined chemotherapy | 14 (19.7) | | Conventional chemotherapy | 57 (80.3) | | Treatment | | | Novel group | | | R-combined CTx; R-CVP, R-CHOP | 6 (8.5) | | VD | 5 (7.0) | | TD | 2 (2.8) | | Bendamustine plus prednisolone | 1 (1.4) | | Conventional group | | | Chlorambucil | 25 (35.2) | | CVP or CHOP | 14 (19.7) | | MP or CP | 15 (21.1) | | FC or FCM | 3 (4.2) |
|
|
ALC: absolute lymphocyte count; CRP: C-reactive protein; LDH: lactate dehydrogenase; BM: bone marrow; ECOG: Eastern Cooperative Oncology Group performance status; ISS: international staging system; R-combined CTx: rituximab combined chemotherapy; R-CVP: rituximab, cyclophosphamide, vincristine, and prednisolone; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; VD: bortezomib plus dexamethasone; TD: thalidomide plus dexamethasone; MP: melphalan plus prednisolone; CP: cyclophosphamide plus prednisolone; FC: fludarabine plus cyclophosphamide; FCM: fludarabine plus cyclophosphamide and mitoxantrone.
|
